PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or
“PAVmed”), a highly differentiated, multi-product, commercial-stage
medical technology company, today announced that prominent global
industry executive Aster Angagaw has joined the Board of Directors
of its majority owned subsidiary Lucid Diagnostics Inc. (“Lucid”).
Ms. Angagaw will serve on the Company’s Audit and Nominating
Committees.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210803005717/en/
Global industry executive Aster Angagaw
joins PAVmed's subsidiary Lucid Diagnostics’ Board of Directors
(Photo: Business Wire)
“I am delighted to welcome Aster Angagaw to Lucid’s Board of
Directors,” said Lishan Aklog M.D., PAVmed’s Chairman and Chief
Executive Officer and Lucid’s Executive Chairman. “She brings
decades of business experience as a chief executive, global
transformation leader, and public company director, with deep
longstanding roots in the global healthcare sector. Her experience
working with large integrated healthcare delivery networks and
knowledge of medical technology supply chain systems will be
particularly valuable to our growing commercial activities. With
Ms. Angagaw joining recent appointees, Stanley Lapidus and Dr.
Jacque Sokolov, Lucid has a world-class board of directors with the
diverse skills and experience to provide critical guidance as we
seek to execute on our ambitious long-term growth strategy.”
“I have spent my career focused on mission-oriented
organizational transformation and strategic operational execution,
much of it while navigating the complexities of the healthcare
industry,” said Ms. Angagaw. “I am very excited to join this
rapidly-growing and innovative medical technology company with a
clear vision and mission to save lives through widespread precancer
screening using cutting-edge technologies. I look forward to
working with Dr. Aklog, Lucid’s strong management team, and my
esteemed board colleagues. Together we have a unique opportunity to
execute this important mission.”
Ms. Angagaw currently serves as a member of the Board of
Directors of Owens & Minor Inc. (NYSE: OMI), a leading
healthcare logistics company providing vital supply chain services
to healthcare providers and manufacturers of healthcare products,
from disposable medical supplies to devices and implants. She
recently served as President of ServiceMaster Brands, the $2.6
billion revenue franchise services division of ServiceMaster Global
Holdings Inc. (NYSE: SERV), a leading provider of essential
services to residential and commercial customers. Last year, Ms.
Angagaw guided the sale of the division to a private equity firm
for $1.6 billion. Prior to ServiceMaster, she served in a series of
senior executive roles at Sodexo SA (Euronext: SW), a
Paris-headquartered multinational diversified services company with
440,000 employees and over $20 billion in revenue. Over 23 years at
Sodexo, she had a successful record of accomplishment in
operations, strategy and business development, organizational
transformation, and customer retention. She rose to become Chief
Executive Officer, Healthcare North America, overseeing 6,000
employees providing services as well as facilities and clinical
technology management to top-rated hospitals and children’s
oncology centers in the US and Canada. Notable prior roles at
Sodexo included serving as a member of its Healthcare Global
Executive Committee, Senior Vice President, Global Head of Sales
and Business Development, responsible for directing business
development and creating a unified global sales organization for
the global Healthcare segment, and Group Vice President for Global
Transformation, where she helped lead a transition from
country-specific business units to a unified global model.
Ms. Angagaw has received numerous honors and has been named
multiple times to Black Enterprise magazine’s list of the Most
influential Black Executives in Corporate America and Most Powerful
Women in Business, as well as Savoy magazine’s list of the Top
Influential Women in Corporate America. She also received the
Diversity Leadership Council’s Leadership Excellence Award. In
2020, Aster was awarded the distinguished 400 Award from 400 years
of African American History Commission.
She serves on the advisory board of the Women in Business
Collaborative, an alliance of businesswomen’s organizations working
together to achieve equal position, pay and power for all women in
business. She is also a member of the Executive Leadership Council,
national organization comprising current and former Black CEOs and
senior executives at Fortune 1000 and Global 500 companies, which
has worked to build an inclusive business leadership pipeline and
seeks to open channels of opportunity for the development of Black
executives to positively impact business and our communities.
Ms. Angagaw received her bachelor’s degree in Organizational
Management from Eastern University in Pennsylvania and an M.B.A.
from the Fox School of Business at Temple University. She is also a
graduate of the Harvard Business School Advanced Management
Program.
About PAVmed and Lucid
PAVmed Inc. is a highly differentiated, multi-product,
commercial-stage medical technology company with a diversified
product pipeline addressing unmet clinical needs encompassing a
broad spectrum of clinical areas with attractive regulatory
pathways and market opportunities. Its major subsidiary, Lucid
Diagnostics Inc., markets the first and only commercial tools for
widespread early detection of esophageal precancer and cancer – the
EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell
Collection Device. Its GI Health division also includes the
complementary EsoCure™ Esophageal Ablation Device with Caldus™
Technology. Another major subsidiary, Veris Health Inc., is a
digital health company developing the first intelligent implantable
vascular access port with biologic sensors and wireless
communication to improve personalized cancer care through remote
patient monitoring. Its Minimally Invasive Interventions division
markets its CarpX® Minimally Invasive Device for Carpal Tunnel
Syndrome. Other divisions include Infusion Therapy (PortIO™
Implantable Intraosseous Vascular Access Device and NextFlo™
Intravenous Infusion Set), and Emerging Innovations (non-invasive
laser-based glucose monitoring, pediatric ear tubes, and mechanical
circulatory support). For more information, please visit
www.pavmed.com, follow us on Twitter, connect with us on LinkedIn,
and watch our videos on YouTube. For more information on our
majority owned subsidiary, Lucid Diagnostics Inc., please visit
www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on
LinkedIn. For detailed information on EsoGuard, please visit
www.EsoGuard.com and follow us on Twitter, Facebook and
Instagram.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements, based upon the current beliefs and expectations of
PAVmed’s management, are subject to risks and uncertainties, which
could cause actual results to differ from the forward-looking
statements. Risks and uncertainties that may cause such differences
include, among other things, volatility in the price of PAVmed’s
common stock, Series W Warrants and Series Z Warrants; general
economic and market conditions; the uncertainties inherent in
research and development, including the cost and time required
advance PAVmed’s products to regulatory submission; whether
regulatory authorities will be satisfied with the design of and
results from PAVmed’s preclinical studies; whether and when
PAVmed’s products are cleared by regulatory authorities; market
acceptance of PAVmed’s products once cleared and commercialized;
our ability to raise additional funding and other competitive
developments. PAVmed has not yet received clearance from the FDA or
other regulatory body to market many of its products. The Company
has been monitoring the COVID-19 pandemic and its impact on our
business. The Company expects the significance of the COVID-19
pandemic, including the extent of its effect on the Company’s
financial and operational results, to be dictated by, among other
things, the success of efforts to contain it and the impact of
actions taken in response. New risks and uncertainties may arise
from time to time and are difficult to predict. All of these
factors are difficult or impossible to predict accurately and many
of them are beyond PAVmed’s control. For a further list and
description of these and other important risks and uncertainties
that may affect PAVmed’s future operations, see Part I, Item IA,
“Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K
filed with the Securities and Exchange Commission, as the same may
be updated in Part II, Item 1A, “Risk Factors” in any Quarterly
Report on Form 10-Q filed by PAVmed after its most recent Annual
Report. PAVmed disclaims any intention or obligation to publicly
update or revise any forward-looking statement to reflect any
change in its expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210803005717/en/
Investors Mike Havrilla Director of
Investor Relations 814-241-4138 JMH@PAVmed.com
Media Katie Gallagher / Kristi
Bruno LaVoieHealthScience (617) 792-3937 / (617) 865-3940
PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Sep 2023 to Sep 2024